

IOM Committee Meeting


Global Fund
February, 2005

- Introduction to performance based funding
- Status and Results
- Issues for discussion


- Core role of performance based funding in the Global Fund
- Using performance data for decisions
 - Innovative system in place
 - Real challenges and learning
- Collaborating with partners to embed M&E
 - Globally and in countries
 - Role as financing agency

Performance Based Funding is central to the Global Fund

The Global Fund has a mandate to raise and disburse substantial *new* funds in a *transparent* manner to achieve sustained *impact* on HIV/AIDS, TB, and malaria




Measurement Framework for the Global Fund on several levels



Global
Fund
contribution

Key strategic priorities in 2005







Performance tools along grant lifecycle

Release of funds related to performance

Grant Lifecycle




1. Making Performance Based Fundi Reality: decisions on grants




Results to Date

Indicator	Year 1 Target	Year 1 Actual	Percentage of Target
1 Number of people with advanced HIV infection receiving ARV combination therapy per year	1200	595	50%
2 Training of personnel to provide home care services	516	1266	245%
3 Number of districts teams trained in home care	28	34	121%
4 Number of mother/child pairs reached with PMTCT services	600	250	42%
5 Number of new centers offering PMTCT services	7	9	129%
6 Number of income-generating projects for PLWHAs	24	15	63%
7 Number of patients treated for OIs	3000	1178	39%
8 Number of new health facilities capable of providing advanced interventions for prevention and medical treatment for HIV infected persons	2	2	100%
9 Number of people attending for VCT	1560	1745	112%
10 Number of new VCT centers	8	9	113%




Disbursements to Date

	Date		Amount		Cumulative	
	Expected	Actual	Expected*	Actual	Expected	Actual
1		18/12/02		\$429,599	\$429,599	\$429,599
2	10/05/03	06/06/03	\$755,980	\$1,246,900	\$1,185,579	\$1,676,499
3	10/08/03	11/06/04	\$755,980	\$1,404,088	\$1,941,559	\$3,080,587
4	09/11/03		\$755,980		\$2,697,539	
5	08/02/04		\$755,980		\$3,453,519	
6	09/05/04		\$755,980		\$4,209,499	



- ABC Grading of Grants
 - Year 1
 - Phase 2



- M&E support to grants

3. Making sense of data



Grant Analysis


- 25 grants
- Country sheets



Portfolio estimates

- High level coverage targets
- Results reports (June, Jan)

4. Independent Evaluations



Measuring the Global Fund Principles

		Global Fund Principles	No. of Indicators
Additionality	Leverage additional financing globally, closing the gap	Purpose and Principles 2 and 3	1
	Externalities: reducing poverty, increasing health human resources		2
	Improve purchasing economy and efficiency for key commodities		1
Sustainability	Improve sustainability and manage risk	Purpose, Principles 2 and 3	6
Improve Partnerships	Global partnerships and harmonisation	Purpose and Principle 3, 7	1
	Country partnerships and harmonisation		1
	Effective CCM composition and functioning		7

- Introduction to performance based funding

- Status and Results

- Issues for discussion

Portfolio and grant results

Portfolio results

In 2004, Global Fund grants financed interventions that reached:

- 130,000 people with antiretroviral treatment for AIDS;
- more than one million people with voluntary HIV testing;
- 385,000 patients with treatment under the DOTS strategy for tuberculosis control;
- more than 300,000 people with highly effective artemisinin-combination treatments for malaria; and
- more than 1.35 million families with insecticide-treated mosquito nets.

Grants

Phase 2 grants: 70% reached targets, 22% inadequate but showed potential, 8% unacceptable performance

Developing the measurement framework: status and next steps

	Level	Framework Status	Measurement examples	Implementation targets
4	<i>Impact</i>	<ul style="list-style-type: none"> - Impact indicators defined in M&E toolkit - Suite of tools implemented to capture targets for grants 	<ul style="list-style-type: none"> - Declining HIV, TB and Malaria mortality - Reduced incidence of HIV, TB and Malaria - Contribution with partners to MDGs, and other international targets 	<ul style="list-style-type: none"> - All Phase 2 grants have impact targets as of January 05 - Contribution to MDGs quantified by Sept 05
3	<i>System</i>	<ul style="list-style-type: none"> - Measurement framework and indicators agreed - Baseline implementation initiated 	<ul style="list-style-type: none"> - Progress in reducing unmet need for AIDS, TB and Malaria spending <ul style="list-style-type: none"> ▪ Inter-Year change in Malaria, TB, HIV spending (all sources) > Global Fund grant spending 	<ul style="list-style-type: none"> - CCM baseline survey results in all countries by June 05 - Baseline report on core system effects indicators by Dec. 05 - 100% of GF funding needs contributed for 05
2	<i>Grant</i>	<ul style="list-style-type: none"> - Standard indicators agreed with partners in M&E toolkit - Implemented into all Phase 2 and new grants - Portfolio results for ARVs, DOTS, ITNs 	<ul style="list-style-type: none"> - Coverage: people reached by services - Top 10 coverage indicators - Phase 2 performance grading and evaluations 	<ul style="list-style-type: none"> - 95% of disbursements based on evidence of performance and expenditure in 05 - 100% of all new and phase 2 grants have coverage indicators in 05 - Report on portfolio top 10 coverage indicators by Dec 05
1	<i>Operational</i>	<ul style="list-style-type: none"> - Core indicators implemented - Executive dashboard agreed - LFA study completed 	<ul style="list-style-type: none"> - Actual against target funds disbursed - Funds contributed to amounts pledged - Average time between grant approval and first disbursement 	<ul style="list-style-type: none"> - Internet access to executive dashboard that is updated continuously by March 05

- Introduction to performance based funding
- Status and Results
- Issues for discussion

- Global harmonisation, push down to countries
 - Toolkit, comparable data, joint estimates
 - Huge investment in country mechanisms
- Complimentarity of programs
 - GF three diseases
 - Geographical, program focus, ARV drugs
 - Put together by countries
 - Multilateral arms of programs
- Great opportunity, challenges at countries